KSQ Therapeutics rakes in $76 mln
Cambridge, Massachusetts-based KSQ Therapeutics, a provider of a genome-scale precision functional genomics platform, has secured $76 million in funding. Flagship Pioneering; Polaris Partners, ARCH Venture Partners and Alexandria Equities led the round.
2 October 2017•1 min read
